XYIGF yields 3.87% · JNJ yields 2.13%● Live data
📍 JNJ pulled ahead of the other in Year 6
Combined, XYIGF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of XYIGF + JNJ for your $10,000?
Xinyi Glass Holdings Limited, an investment holding company, produces and sells automobile, construction, float, and other glass products for commercial and industrial applications. The company operates through three segments: Float Glass, Automobile Glass, and Architectural Glass. It is also involved in the manufacturing and sale of automobile rubber and plastic components, as well as electronic glass; trading of automobile glass; and research and trading of glass. In addition, the company offers logistic and related services; supply chain services; operates a wind farm for electricity generation; and manufactures automatic machines for solar glass factory and other glass related industries, as well as holds properties and car parks. The company serves automobile glass manufacturing; wholesale and distribution; automobile repair; motor vehicle manufacturing; curtain wall engineering and installing; architectural and furniture glass manufacturing; electronic and household appliances manufacturing; and float glass wholesale and distribution companies. It sells its products in approximately 140 countries and territories, including the People's Republic of China, Hong Kong, the United States, Canada, Australia, and New Zealand, as well as countries in Asia, the Middle East, Europe, Africa, and the Americas. The company was founded in 1988 and is headquartered in Kwun Tong, Hong Kong.
Full XYIGF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.